Atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system is a highly malignant, pediatric brain tumor typically arising de novo. Inactivation of SMARCB1 is a defining molecular event. We present here a rare case of an adult (35 years) low-grade SMARCB1-deleted brain tumor with transition into prototypical AT/RT over 14 years. Molecular analysis was performed for 3 tumor presentations including copy number analysis, DNA methylation analysis (450k), and whole exome sequencing. We detected the identical somatic SMARCB1 deletion at all 3 time-points. In an unsupervised hierarchical clustering of methylation data together with 127 reference cases comprising 9 brain tumor classes all 3 manifestations clustered with AT/RT. Exome sequencing revealed an increase of mutational burden over time. The acquired mutations and additional copy number changes did not affect known cancer genes.
INTRODUCTION
Atypical teratoid/rhabdoid tumor (AT/RT) of the CNS is an aggressive, embryonal brain tumor that consists either of predominantly rhabdoid cells or of a mixture of rhabdoid cells with additional primitive neuroectodermal, mesenchymal, and/or epithelial elements (1) . AT/RT is rarely diagnosed in patients older than 5 years (2) . A recent review identified only 31 published adult AT/RT cases (3) . While pediatric AT/RT usually follow a detrimental course, adult AT/RT behavior may vary with survival times between 2 weeks and >15 years (3) .
The defining molecular event for both pediatric and adult AT/RT is inactivation of the SMARCB1 (BAF47/hSNF5/INI1) tumor suppressor gene on chromosome 22q11.2, either by deletion or mutation (4) . The vast majority of AT/RTs develops de novo without precursor lesions. There are, however, single reported exceptions: 3 pleomorphic xanthoastrocytomas in 8, 13, and 23-year-old patients (5-7) and 3 low-grade gangliogliomas in 6, 11, and 11-year-old patients (6, 8, 9 ) are documented to have progressed into an AT/RT. Slightly disturbing, all these cases were demonstrated to harbor a BRAF V600E mutation in both the initial tumor and the AT/RT. This alteration is not recurrently described for AT/RT but typically observed in ganglioglioma, pleomorphic xanthoastrocytoma, and anaplastic pleomorphic xanthoastrocytoma . Recently, a 24-year-old patient with a RELA fusion-positive BRAF wildtype ependymoma presenting with a predominant INI1 negative rhabdoid cell component was described and interpreted as an AT/RT arising from ependymoma (13) .
Several studies focusing on the molecular genetics of AT/RT have recently been published. Using the OncoMap array Kieran et al described an absence of canonical pathway alterations in pediatric AT/RTs (age from 4 months to 10 years, n ¼ 25) (14) . Lee et al present similar results using whole exome sequencing (patient age from 0.25 to 60 months, n ¼ 35) detecting no recurrent mutations with the exception of alterations of SMARCB1 (15). Hasselblatt et al found alterations affecting the SMARCB1 locus in 94% of examined cases using the OncoScan FFPE MIP SNP Array patient age from 0 to 24 months (n ¼ 16), but no recurrent alterations of other cancer relevant genes (16) . In addition, heterogeneity amongst AT/RT is now being acknowledged, with the identification of distinct molecular subgroups (17, 18) . However, very little data exist on the genetics of adult AT/RT.
We here describe an exceedingly rare case of transformation of a SMARCB1-deleted low-grade brain tumor into an AT/RT over a time-course of 14 years. Extensive molecular analysis was performed for the initial tumor presentation as well as the first and second relapse. While SMARCB1 deletion was present at all time-points, we observed a stepwise increase of somatic mutational burden and copy number alterations from the histologically benign first tumor to the prototypical AT/RT 14 years later. Our results may give initial indications towards relevant factors in the progression of AT/RT and also demonstrate that SMARCB1 deletion alone is not sufficient to drive a malignant tumor in adults.
Clinical Case
A 35-year-old man with mild mental retardation of unknown origin from birth, presented with newly developed generalized seizures in the year 2000. MRI scan revealed a right frontal suprasylvian tumor without contrast-enhancement and with diffuse edema involving the complete frontal lobe suggestive of a low-grade brain tumor. Because of increasing seizure frequency, gross-total resection of the tumor was performed in 2002 (Fig. 1) . The lesion was histologically diagnosed as an unusual low-grade brain tumor with extensive diffuse cortical infiltration, interpreted as a low-grade diffuse glioneuronal tumor at initial diagnosis ( (Fig. 1) . The tumor was then stable in subsequent follow-up MRI scans. In 2010, 6 years after radiation, MRI revealed new contrast enhancement at the right temporal lobe not associated with new clinical symptoms. This finding was further monitored. After 2 years of followup without clinical deterioration, the patient (now aged 47 years) presented with generalized seizure episodes refractory to intensified medical treatment. MRI scan revealed a progressive new contrast enhancement showing diffuse infiltration of the right temporal lobe (Fig. 1) . The patient therefore underwent a partial temporal lobe resection. Histologically, the second lesion was highly reminiscent of the initial tumor tissue, leading to the diagnosis of an unusual diffuse low-grade tumor not clearly classifiable. Again, INI1 loss was demonstrated by immunohistochemistry (not shown). In the MRI scan 6 months after partial temporal lobe resection, a massive growth of the right temporal mass was observed (Fig. 1) . The patient was in reduced clinical condition with a progressive left-sided hemiparesis and aphasia, and a stereotactic biopsy was performed. The lesion now presented as a highly malignant tumor with extensive rhabdoid features, compatible with the diagnosis of AT/RT (Fig. 3c, d ). Further oncological therapy was not possible due to the reduced clinical state of the patient. As CT imag- ing showed further progression of the tumor and beginning of uncal herniation, therapy was interrupted and the patient was transferred to a palliative care unit. The patient died 1 month after diagnosis of AT/RT.
Molecular Characterization
To further clarify the molecular basis as well as molecular progression, SNP array copy number analysis and 450k methylation profiling (both of tumor manifestations 1-3) and exome sequencing (tumor manifestation 2-3) were performed.
SMARCB1 Deletion Is Observed in All 3 Tumor Manifestations but Not in Germ Line
Affymetrix OncoScan array (tumors 1, 2 and blood only; Affymetrix, Inc., Santa Clara, CA) and Illumina Human Methylation450 bead array analysis (tumors 1, 2, and 3; Illumina, San Diego, CA) was used to investigate copy number alterations (19, 20) . Deletion of SMARCB1 was present in all tumors but not in the matched germ-line sample (Fig. 4) . Besides loss of SMARCB1 the initial tumor showed a focal deletion on chromosome 10q of unknown significance. This alteration was retained in the subsequent tumors. Additional small deletions were observed in the second manifestation affecting Chr 1, 4, and 5 that were also retained in the third manifestation ( Fig. 5 ; for details see Supplementary Data Table S1 ). New gains/amplifications or deletions of known cancer genes were not observed. Even in the last (highly malignant) lesion, the total number and complexity of copy number alterations was relatively low.
450k Methylation Profiling Demonstrates High Resemblance of All 3 Tumor Manifestations to AT/RT
DNA methylation profiling has demonstrated high potential for tumor classification . To clarify the relation of this unusual tumor to other types of brain tumors, all 3 manifestations were subjected to Illumina Human Methylation 450 bead array analysis and compared with the methylation profiles of relevant reference cases (AT/RT as well as various glioblastoma subtypes, astrocytoma, ganglioglioma, pleomorphic xanthoastrocytoma, and dysembryoplastic neuroepithelial tumor). Unsupervised hierarchical clustering (Ward's linkage method) of the 20 000 CpGs with the highest median absolute deviation across the beta values was performed. Pairwise similarity was calculated using Euclidian distance.
As expected, the reference tumors formed distinct clusters (Fig. 6 ). Not surprisingly, the third manifestation with the histology of AT/RT clustered within the AT/RT reference cases. Slightly unexpectedly both the initial tumor and the first recurrence also tightly clustered with the group of AT/RT, despite their histology of a low-grade brain tumor. Within AT/ RT, 2 subclusters were detected with all 3 manifestations of the presented case falling into the same subcluster (Fig. 6) . Interestingly, this subcluster was enriched for higher patient age (the other cases being 4, 20, 26, and 66 years), whereas the 
Acquisition of Coding Mutations During Tumor Evolution
Exome sequencing using Agilent SureSelect v4 (Agilent Technologies, Inc., Santa Clara, CA) in-solution reagents for exome capture and Illumina HiSeq 2000 for paired-end sequencing was performed on frozen tissue of tumor 2 and tumor 3 and on patient blood. For all detected coding somatic mutations, direct sequencing in the initial manifestation (tumor 1, only paraffin tissue available) was performed by standard protocols.
Whole exome sequencing reads were aligned using BWA and single nucleotide variants (SNVs) and indels were detected from uniquely aligned reads (mapping quality > 0) as previously described (29) (30) (31) . We considered only exonic SNVs/indels predicted to affect the encoded protein (nonsynonymous, stopgain, stoploss, splice sites) as well as those in noncoding genes (ncRNA). On-target coverage was 142-fold (blood), 124-fold (tumor 2), and 97-fold (tumor 3).
In total, 46 SNVs affecting 45 genes were identified by whole exome sequencing of tumor 2 and tumor 3 (see Supplementary Data Table S2 for full details). To reduce the number of alterations to the ones with putative relevance, PolyPhen-2 (Polymorphism Phenotyping v2) was used to classify all missense mutations in probably damaging, possibly damaging or benign (32) . Mutations with benign prediction were not further considered. This reduced the number of alterations to 28. Figure 7 illustrates the overlap of alterations between the 3 manifestations. The distribution of mutations strongly argues for a clonal evolution of all 3 lesions with slight subclonal differences between manifestations 2 and 3. We did not observe obvious oncogenic mutations in any of the manifestations.
DISCUSSON
Most AT/RTs develop in infants and young children and without precursor lesions of lower malignancy. We here give detailed clinical and molecular data on the very rare instance of an adult AT/RT developing from a benign low-grade brain tumor over the course of 14 years. The final lesion of the presented case was indistinguishable from pediatric AT/RT by histology, INI1 loss, methylation profile and the highly malignant clinical behavior. Stringent molecular analysis of all 3 lesions of this patient gives important insight into the development of AT/RT that may be applicable for both adult and pediatric tumors.
SMARCB1 Loss Is Not Sufficient for the Development of Adult AT/RT
All 3 lesions of our presented case harbored the identical focal SMARCB1 deletion. The initial tumor showed only minimal progression for over 10 years. This clearly indicates that, at least for adult patients, SMARCB1 deletion is not sufficient to develop the classical phenotype of AT/RT. There have been previous reports in the literature of gangliogliomas and pleomorphic xanthoastrocytomas developing to AT/RT (5-9). In these cases the time from initial tumor to malignant development was between 2 weeks and 8 months and the age range was between 6 years and 23 years. All of these cases shared a BRAF V600E mutation, which is common for pleomorphic xanthoastrocytoma, and ganglioglioma, but not for AT/RT and other gliomas (10-2). Our case differs from the above cases not only by the time course of tumor development and patient age, but also by lacking a BRAF V600E mutation. Table S2 . Alterations in tumor 2 (first recurrence) and tumor 3 (second recurrence) were detected by whole exome sequencing. Presence or absence of these was then investigated by individual Sanger sequencing in the initial presentation (tumor 1).
Adult AT/RT and Distal 22q Deletion Syndrome
locus of SMARCB1. They hypothesize that this germline deletion syndrome might function as a first genetic hit for the later development of AT/RT in adulthood. In contrast to this case, the deletion of SMARCB1 in the tumors of our patient was not observed in the germ line. Interestingly, we did observe a small deletion of 22q11.23 also in germ line (chr22:24.346.428-24.390.318), but this did not include SMARCB1. The deleted region spans 40 000 bases and is centered on the GSTT1 gene that is known to be haplotype-specific and to be absent from around one third of the population. Thus, this small deletion likely represents an unrelated polymorphism, although we cannot completely exclude an association with the development of AT/RT. Interestingly, our patient additionally had a mental retardation of unknown origin from birth, possibly indicating some form of syndromic disease; however, other features of distal 22q11.2 deletion syndrome were not evident.
DNA Methylation Profile Is Determined Early in AT/RT Evolution
Slightly surprisingly, even the methylation profile of the initial tumor with benign histology was highly reminiscent to the methylation profile of pediatric AT/RT. Further, the DNA methylation profile of all 3 tumor manifestations was remarkably similar. By current understanding, the DNA methylation profile of a tumor is likely determined by characteristics reflecting the cell of origin and in some instances also by specific mutations that interfere with DNA methylation (eg IDH1 point mutations) (34, 35) . This would indicate that possibly SMARCB1 alterations also contribute to shaping the methylation profile of respective tumors or that the cell of origin of our analyzed adult AT/RT may be highly related to the cell of origin of pediatric AT/RT. In the latter scenario, one could speculate that the different clinical behavior between these 2 age groups may be a result of either proliferative potential of the cell of origin or of the different stimulatory potential of the surrounding brain tissue that is likely very different between an infant and an adult patient as in the presented case.
DNA Methylation Profiling for the Diagnosis of Adult AT/RT
DNA methylation profiling has substantial potential for diagnostic tumor classification. In the case presented here, the malignant potential of the initial tumor was indicated by the methylation profile reminiscent of an AT/RT. Initial histopathology of the tumor was not suspicious for a malignant tumor and was interpreted as an unusual diffuse glioneuronal brain tumor. On the other hand, this shows that caution may be required in the interpretation of adult AT/RT methylation profiles, as despite the typical methylation profile of an AT/RT, the clinical behavior of the initial tumor was not consistent with that of an AT/RT for many years.
Even in the revised fourth edition of the WHO classification of brain tumors (1), a diagnostic category that would fit the presented cases is lacking. With the more widespread implementation of methylation profiling in clinical practice it seems possible that more cases with this molecular profile and clinical behavior may be detected, possibly at some stage becoming an own variant of AT/RT developing from a precursor lesion.
Mutation Profile of Adult AT/RT
Adult AT/RT cases have so far not been examined using whole exome sequencing. Nevertheless there are some whole exome sequencing or next generation sequencing data for AT/ RT in children. Studies by Lee et al (15) , Kieran et al (14) , and Hasselblatt et al (16) presenting in total 73 tumor samples obtained from pediatric patients not older than 10 years, found an altogether relatively low rate of mutations and no recurrent alterations other than SMARCB1 loss/mutation. Comparison of the mutated genes of our cases with the above pediatric cases also did not reveal recurrent alterations besides SMARCB1.
Unique about the present case was our possibility to examine the progression of an AT/RT from a relatively benign phenotype to an undifferentiated, aggressive tumor over the time course of several years. Although in tumor sample 1 we found clearly fewer SNVs and copy number variants than in tumor samples 2 and 3, the detected mutations in the latter lesions are not in genes known to play a key role in carcinogenesis or cell behavior (although it cannot be excluded that alterations seen in the last tumor may be associated with malignancy). Almost all of the mutations seen in the last tumor are probably affecting gene function (as assessed using PolyPhen-2). The observed mutations in the genes PIP, KRT15, and SMG may be of slightly higher interest, as mutations in these genes have at least been observed as mutated in other types of cancer (CNS, kidney and hematopoietic malignancies) (36) . Our molecular techniques do not allow detection of fusion genes and will miss most nonexonic mutations, so it is possible that the tumor acquired such alterations. The role of radiotherapy between tumor manifestation 1 and 2 as a possible causative factor for the acquisition of mutations and copy number alterations also remains unclear.
Conclusion
In conclusion, we have presented data on the development of an adult AT/RT over the course of 14 years. We demonstrate that SMARCB1 deletion is not sufficient for the development of a malignant phenotype in adult AT/RT. Our case further suggests that the precursor lesions of adult AT/RT show high molecular resemblance with end stage adult AT/RT in respect to the presence of SMARCB1 deletion and DNA methylation profile, but harbor fewer mutations and copy number alterations. The acquired mutations and acquired copy number changes of our case do not affect known cancer genes and may also represent random genetic events or may be related to radiotherapy. Our observation of a stable disease course for nearly 10 years in a tumor with SMARCB1 loss and an AT/RT DNA methylation profile indicates that caution may be required in the diagnostic interpretation of such findings in adult patients.
